Skip to content
WyteRock E-Books

WyteRock Blog

European Health Data Space: the first implementing rules are in force

WyteRock Global · 2026-11-01

Three Commission implementing regulations under the European Health Data Space entered into force on 11 and 12 October 2026. They set the rules for cross-border patient data, patient identification and the description of health datasets. Most of their obligations apply from 2027 or 2029, but the preparatory work starts now, and a consultation on data-access templates closes on 13 November 2026.

Regulation (EU) 2025/327, the European Health Data Space (EHDS) Regulation, was adopted on 11 February 2025 and published on 5 March 2025. It has two halves. The first, "primary use", gives patients electronic access to their own health data and lets that data move with them across borders. The second, "secondary use", obliges organisations that hold health data to make it available, through national health data access bodies, for research, innovation, regulation and policy. Much of the detail was left to implementing acts. The first three of those acts were published in the Official Journal on 21 and 22 September 2026.

The three regulations

Regulation Subject In force Applies from
(EU) 2026/2083 MyHealth@EU, the central platform for cross-border exchange of patient data 11 October 2026 26 March 2027
(EU) 2026/2099 Cross-border identification and authentication of patients, health professionals and providers 12 October 2026 26 March 2027 (Articles 3(3) and 5(2) from 26 March 2029)
(EU) 2026/2098 Minimum metadata for dataset descriptions for secondary use 11 October 2026 26 March 2029

MyHealth@EU (2026/2083). The Commission will provide four central services: reference software for national contact points for digital health, a central terminology service, a secure communication network and a central configuration service. A national contact point must pass a compliance check and a technical test without critical findings before it may exchange data. Any finding, whatever its level, requires an action plan within 15 working days. Compliance is rechecked every five years, and significant incidents must be notified within 24 hours. Contact points that already exchange data under the current eHealth infrastructure before 26 March 2029 are deemed authorised.

Identification (2026/2099). Each Member State must define a national set of "healthcare attributes" used to identify a patient for cross-border exchange, and notify it to the Commission by 26 March 2028. From 26 March 2029, patients may hold those attributes as an electronic attestation in their European Digital Identity Wallet, and providers requesting data through MyHealth@EU must accept it. Electronic identification must reach eIDAS assurance level "substantial" now, and level "high" from 26 March 2030 for patients and from 26 March 2032 for health professionals.

Dataset metadata (2026/2098). This is the act with the widest commercial reach. Under Article 60(3) of the EHDS Regulation, every health data holder must describe each dataset it holds to its health data access body and check the description at least annually. The new regulation fixes 27 minimum metadata elements, which must be expressed in HealthDCAT-AP, the Commission's health extension of the DCAT application profile. They include the coding system (for example ICD-10-CM or SNOMED CT), whether the dataset contains personal data, the number of records, the estimated number of unique individuals, temporal and geographical coverage, provenance and a structured description of the variables.

Who counts as a health data holder

The definition in Article 2 is broad. It covers healthcare providers and public bodies, and also any natural or legal person developing products or services for the health, healthcare or care sectors, developing or manufacturing wellness applications, or performing health research, where it processes personal electronic health data as controller or controls non-personal data through product design. Only natural persons and microenterprises are exempt (Article 50), and Member States may remove even that exemption.

The categories that holders must make available (Article 51) include electronic health record data; data from clinical trials, clinical investigations and performance studies under the clinical trials regulation, the MDR and the IVDR; health data generated by medical devices; data from registries for medicinal products and medical devices; and data from wellness applications and biobanks. Some categories, including clinical-study data, apply only from 26 March 2031.

The wider timetable

Date Milestone
26 March 2027 General application of the EHDS Regulation; deadline for implementing acts such as the access templates (Article 70) and the European electronic health record exchange format (Article 15)
26 March 2029 Secondary-use chapter applies; patient summaries, e-prescriptions and e-dispensations, and EHR systems processing them
26 March 2031 Medical imaging, laboratory results and discharge reports, and EHR systems processing them; further secondary-use categories

The open consultation

On 16 October 2026 the Commission opened feedback on a draft implementing act setting common templates for the health data access application, the data permit and the health data request (Articles 67 to 70). Feedback closes at midnight Brussels time on 13 November 2026. These templates will define what a company, hospital or university must state to obtain data for research, product development or algorithm training, so applicants have a direct interest in their content.

What this means for you

Medical device and IVD manufacturers. Article 53 allows access to EHDS data for scientific research that includes "training, testing and evaluation of algorithms, including in medical devices, in vitro diagnostic medical devices, AI systems and digital health applications". From 2029, national catalogues built on these 27 metadata elements will show what data exists, where, and in what coding. That is a new source of real-world evidence for clinical evaluation and post-market follow-up. At the same time, a manufacturer that holds patient data from studies, registries or connected devices may itself be a data holder. A manufacturer that claims its device is interoperable with EHR systems must also prove compliance with the EHDS interoperability and logging requirements (Article 27).

Hospitals and laboratories. These institutions hold most of the data the EHDS targets. The metadata regulation turns "describe your datasets" into a defined, machine-readable exercise, and the identification regulation will change how foreign patients are identified at the point of care.

Investors. Data assets in a health-technology company will become more visible and, in some cases, subject to access obligations against cost-based fees (Article 62). Due diligence should ask whether a target is a data holder, which datasets it would have to describe, and whether its evidence strategy can draw on EHDS access.

What to do now

  1. Map your datasets against the Article 51 categories and decide, entity by entity, whether you are a health data holder or exempt.
  2. Run a metadata dry-run. Describe one key dataset against the 27 elements in HealthDCAT-AP. Gaps in variables, coding and provenance usually surface quickly.
  3. Respond to the templates consultation by 13 November 2026 if you expect to apply for data.
  4. Build EHDS access into your evidence plan. For devices and AI products in development, consider where secondary-use data could support clinical evaluation or performance claims from 2029. WyteRock's clinical evidence planning service covers this step, and a single scoped question can go through the fixed-price Task Request service.
  5. Align data governance with the AI Act. Algorithm training on health data now sits at the intersection of the EHDS, the GDPR and the AI Act; Who Is in Control?, one of the WyteRock e-books, sets out the AI Act questions for medicine.

Alex Mansour is CEO of WyteRock Global, a France-based life-sciences advisory firm that supports manufacturers, laboratories and investors on clinical evidence planning and EU market access.

Sources

  1. Regulation (EU) 2025/327 on the European Health Data Space (OJ L, 2025/327, 5.3.2025): Articles 2, 14, 15, 27, 50, 51, 53, 60, 70, 77 and 105. EUR-Lex: https://eur-lex.europa.eu/eli/reg/2025/327/oj/eng
  2. Commission Implementing Regulation (EU) 2026/2083 of 18 September 2026 on MyHealth@EU (OJ L, 21.9.2026): Articles 3, 8 to 10, 13, 18 and 19. EUR-Lex: https://eur-lex.europa.eu/eli/reg_impl/2026/2083/oj/eng
  3. Commission Implementing Regulation (EU) 2026/2099 of 21 September 2026 on an interoperable, cross-border identification and authentication mechanism (OJ L, 22.9.2026): Articles 3, 4, 5, 7 and 9. EUR-Lex: https://eur-lex.europa.eu/eli/reg_impl/2026/2099/oj/eng
  4. Commission Implementing Regulation (EU) 2026/2098 of 18 September 2026 laying down the minimum metadata elements for dataset descriptions under Article 77(4) of Regulation (EU) 2025/327 (OJ L, 21.9.2026): Articles 1 to 4 and Annex. EUR-Lex: https://eur-lex.europa.eu/eli/reg_impl/2026/2098/oj/eng
  5. European Commission, HealthDCAT-AP specification. https://data.health.europa.eu/healthdcat-ap/releases/latest/
  6. European Commission, Have Your Say: "Templates for health data access applications, health data requests, data permits and decisions on a data request" (Ares(2026)1211139), feedback 16 October to 13 November 2026. https://ec.europa.eu/info/law/better-regulation/have-your-say/initiatives/16712_en

Get new articles by email. Sign up for the newsletter or join the CentiAgent Club; members receive an alert for every new article.